Some believe that the president’s ill-defined pharma-tariff timeline is a sign he is not serious. For now, that seems like wishful thinking https://t.co/SteUAqSZke ...

【 导读 】 2025年7月22日，中国资本市场这片热土上，一块名为"科创板"的"试验田"已悄然耕耘六载 春秋。6年，是筚路蓝缕的创业史，是硬核科技的淬炼场，更是创新驱动国家战略的生动注 脚。589颗"科创之星"在此汇聚，闪耀着7.3万亿市值的磅礴光芒，它们从核心技术"卡脖 子"的困境中破土，在新质生产力的浪潮里拔节，共同编织着中国产业升级与科技自立自强的 宏大叙事。 值此承前启后的重要时刻，我们特别邀约了数位深耕于科创板沃土的领航者——他们是前沿 赛道的开拓者，是实验室到生产线奇迹的缔造人。褪去资本市场的喧嚣，这些掌舵人欣然提 笔，以最真挚的笔触，为我们留下了属于这个时代的"科创心语"。此刻，让我们一同静心聆 听，这些搏击于时代潮头的灵魂之声，如何汇成推动中国科创巨轮驶向星辰大海的澎湃涛 声。 海光信息总经理沙超群 正逢科创板开市 六 周年，海光信息也即将上市满 三 年。科创板为科 技企业提供了一个更加开放、包容、高效的资本市场环境，得益于科 创板丰沃的投融资土壤以及政策 " 工具箱 " ，海光信息近年来不断在 公司治理能力、创新能力、竞争能力和经营能力上取得显著进展。 海光在芯片市场取得的长足发展，离不开 ...

Yuting Yang +852-2978-7283 | yuting.y.yang@gs.com 21 July 2025 | 8:00PM HKT China Matters Waiting for the Slowdown (Shan) Andrew Tilton +852-2978-1802 | andrew.tilton@gs.com Goldman Sachs (Asia) L.L.C. Hui Shan +852-2978-6634 | hui.shan@gs.com Goldman Sachs (Asia) L.L.C. Lisheng Wang +852-3966-4004 | lisheng.wang@gs.com Goldman Sachs (Asia) L.L.C. Xinquan Chen +852-2978-2418 | xinquan.chen@gs.com Goldman Sachs (Asia) L.L.C. Waiting for the Slowdown (Shan) Despite external tariff turbulences and ongoing stru ...

Core Viewpoint - A class action lawsuit has been filed against UroGen Pharma Ltd. for alleged misleading statements regarding its lead product UGN-102, which is intended for treating low-grade intermediate risk non-muscle invasive bladder cancer [1][2]. Group 1: Lawsuit Details - The lawsuit covers investors who acquired UroGen securities between July 27, 2023, and May 15, 2025, with a deadline of July 28, 2025, to apply as lead plaintiff [1]. - Allegations include that UroGen's ENVISION clinical study for UGN-102 was inadequately designed, lacking a concurrent control arm, which undermined the evidence of effectiveness [3]. - The FDA had previously warned UroGen about the study design, suggesting a randomized trial, which UroGen did not conduct [4]. Group 2: Stock Price Impact - Following the FDA's briefing document on May 16, 2025, which raised concerns about the study's interpretability, UroGen's stock price fell nearly 26% [4]. - On May 21, 2025, after the Oncologic Drugs Advisory Committee voted against the approval of UGN-102, the stock price dropped nearly 45% [5].

AstraZeneca plans to invest $50 billion in the US before 2030, ratcheting up spending in the country ahead of potential tariffs on imported medicines https://t.co/zu0W9NjXEu ...

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for allegedly misleading investors regarding the viability of its drug candidates, particularly troriluzole and BHV-7000, during the period from March 24, 2023, to May 14, 2025 [1][2]. Group 1: Company Overview - Biohaven Ltd. is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology [1]. - The company is working on several product candidates, including troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder [1]. Group 2: Allegations and Legal Proceedings - The lawsuit alleges that Biohaven overstated the regulatory prospects and data sufficiency for troriluzole's approval for SCA [2]. - It is also claimed that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were similarly overstated [2]. - The complaint suggests that the revelation of these issues could significantly negatively impact Biohaven's business and financial condition [2]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers by September 12, 2025 [3]. - Participation in the class action is not required to be eligible for recovery; shareholders can remain absent class members if they choose [3].

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?I have covered Evolus (NASDAQ: EOLS ) twice before in notes for Seeking Alpha, the first time in March 2024 , issuing a "Buy" recommendation, and re-iterating that rating in a more recent note, inThe group is for b ...

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug candidate ALTO-100 during its IPO and subsequent period [1][2]. Group 1: Company Overview - Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company based in the U.S. with a product pipeline that includes ALTO-100, which was in a Phase 2b clinical trial for treating major depressive disorder (MDD) at the time of its IPO [1]. - The IPO occurred on or about February 2, 2024, and the class period for the lawsuit extends from this date to October 22, 2024 [1]. Group 2: Allegations and Misleading Information - The lawsuit alleges that the Offering Documents related to the IPO were negligently prepared and that the company failed to disclose critical information about ALTO-100's effectiveness [2]. - Specifically, it is claimed that ALTO-100 was less effective in treating MDD than represented, leading to overstated clinical, regulatory, and commercial prospects, which in turn inflated Alto's business and financial outlook [2]. Group 3: Impact of Clinical Trial Results - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to placebo [3]. - Following this announcement, Alto's stock price plummeted by $10.17 per share, a decrease of 69.99%, closing at $4.36 per share on October 23, 2024 [3]. Group 4: Legal Proceedings - Shareholders interested in participating in the class action have until September 19, 2025, to seek lead plaintiff status, which allows them to represent other class members in the litigation [4]. - Participation in the case is not required to be eligible for recovery, and shareholders can choose to remain absent class members [4].

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN). Shareholders who purchased shares of OGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/organon-co-loss-submission-form/?id=157198&from=3 CLASS PERIOD: October 31, 2024 to Apri ...

WARREN, N.J., July 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2025 financial results and provide an update on the company's business and outlook on Thursday, August 7, at 4:30 p.m. ET.To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in for the conference call 15 minutes prior to the start ...